Drug Trial Radar · NCT07493512
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Apr 28, 2026
Primary completion
Jul 30, 2030
Study completion Jul 30, 2030
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Mar 25, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this trial is to determine the safety profile of xaluritamig at the proposed regimen in adult participants with metastatic castration-resistant prostate cancer (mCRPC).
Conditions
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions
XaluritamigDrug
Participants will receive xaluritamig via short-term intravenous (IV) infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment-emergent Adverse EventsTime frame: Up to 3.6 Year
Locations
14 sites in 2 countries. Site status is shown where the registry gives one.
Rocky Mountain Cancer Centers
Denver, Colorado · Recruiting
United States Oncology Regulatory Affairs Corporate Office
Denver, Colorado · Recruiting
US Oncology Research Investigational Products Center
Denver, Colorado · Recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
Oncology Hematology Care Incorporated
Cincinnati, Ohio · Recruiting
Thomas Jefferson University
Philadelphia, Pennsylvania · Recruiting
University of Pittsburgh Medical Center Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
Sanford Oncology Clinic and Pharmacy
Sioux Falls, South Dakota · Recruiting
Sarah Cannon Research Institute Oncology Partners
Nashville, Tennessee · Recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Next Oncology - Dallas
Irving, Texas · Recruiting
Virginia Oncology Associates - Hampton
Norfolk, Virginia · Recruiting
Chris OBrien Lifehouse
Camperdown, New South Wales, Australia · Recruiting
Monash Medical Centre
Clayton, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.